NIH Grants Exclusive License for Brain-Targeting Nano-Drug Tech Platform
Published Date: 4/22/2025
Notice
Summary
The National Cancer Institute plans to give Sangam Lifesciences an exclusive license to use a new drug delivery technology that targets the brain and lymphatic system based on molecule size. This could speed up better treatments for diseases affecting these areas. Interested parties must send comments or license requests by April 22, 2025, or miss out on this opportunity.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Exclusive License Contemplated for Sangam
The National Cancer Institute is contemplating granting Sangam Lifesciences, Inc. an exclusive patent license to practice the listed inventions. The prospective exclusive license territory may be worldwide and would be royalty-bearing and limited to development, manufacture, and commercialization of a poly (L-lysine succinylated) (PLS) alpha-galactosylceramide prodrug for human and veterinary uses in the treatment of cancer.
Exclusivity Limited to Cancer Use
The scope of exclusivity, if granted, will be limited to the PLS-alpha-galactosylceramide prodrug for the treatment of cancers. The notice explicitly states that other fields of use would remain available, including use of the PLS prodrug for non-oncology indications and PLS conjugated to other therapeutic agents.
Application Confidentiality and Objection Rules
Complete license applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information. Comments or objections that are not in the form of a license application will not be treated confidentially and may be made publicly available; license application materials will be released only as required under the Freedom of Information Act (5 U.S.C. 552).
April 22, 2025 Application Deadline
Only written comments and/or license applications received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered. Interested parties who do not submit by that date may not be able to file timely objections or license applications in response to this notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2025-06876, Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities
Some companies want to start or buy businesses that do activities related to banking but aren’t banks themselves. The Federal Reserve is checking these plans and asking the public to share their thoughts by May 7, 2025. This helps keep banking safe and sound while letting companies grow in new ways across the U.S.
Next: 2025-06879, National Center for Advancing Translational Sciences; Notice of Closed Meeting
The National Center for Advancing Translational Sciences is holding a private meeting on May 14-15, 2025, to review secret contract proposals about developing new drug products. This meeting affects companies and researchers involved in drug development and keeps sensitive info safe. No public money changes are announced, but the decisions could impact future drug research funding.